Perrigo (PRGO) Common Equity (2013 - 2026)
Perrigo's (PRGO) quarterly Common Equity came in at $2.5 billion in Q1 2026, down 42.74% year-on-year from $4.4 billion in Q1 2025, and down 14.88% on a QoQ basis from $2.9 billion in Q4 2025.
Perrigo (PRGO) Common Equity (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Common Equity data on file, last reported at $2.5 billion in Q1 2026.
- On a quarterly basis, Common Equity fell 42.74% year-over-year to $2.5 billion in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 42.74% decrease from a year earlier, with the FY2025 full-year figure at $2.9 billion, down 32.04% from the prior year.
- Common Equity for Q1 2026 stood at $2.5 billion, down from $2.9 billion in the prior quarter.
- Over the last five years, Common Equity for PRGO reached as high as $5.1 billion in Q2 2022 and fell as low as $2.5 billion in Q1 2026.
- Historically, Common Equity has averaged $4.4 billion across 5 years, with a median of $4.6 billion in 2022.
- Across the five-year window, Common Equity increased 2.94% in 2023 and plunged 42.74% in 2026, its largest moves.
- Year by year, Common Equity stood at $4.8 billion in 2022, then retreated by 1.53% to $4.8 billion in 2023, then decreased by 9.41% to $4.3 billion in 2024, then slumped by 32.04% to $2.9 billion in 2025, then decreased by 14.88% to $2.5 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $2.5 billion in Q1 2026, $2.9 billion in Q4 2025, and $4.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 2.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 2.50 Bn |
| Dec 31, 2025 | 2.94 Bn |
| Sep 27, 2025 | 4.45 Bn |
| Jun 28, 2025 | 4.47 Bn |
| Mar 29, 2025 | 4.36 Bn |
| Dec 31, 2024 | 4.32 Bn |
| Sep 28, 2024 | 4.57 Bn |
| Jun 29, 2024 | 4.55 Bn |
| Mar 30, 2024 | 4.69 Bn |
| Dec 31, 2023 | 4.77 Bn |
| Sep 30, 2023 | 4.74 Bn |
| Jul 1, 2023 | 4.85 Bn |
| Apr 1, 2023 | 4.83 Bn |
| Dec 31, 2022 | 4.84 Bn |
| Oct 1, 2022 | 4.60 Bn |
| Jul 2, 2022 | 4.85 Bn |
| Apr 2, 2022 | 5.10 Bn |
| Dec 31, 2021 | 5.15 Bn |
| Oct 2, 2021 | 5.18 Bn |
| Jul 3, 2021 | 5.51 Bn |